Novartis
Basel, Switzerland
East Hanover, New Jersey, United States
with other locations globally
United States
Website: http://www.novartis.com/
About Novartis
At Novartis, we are driven by a single mission: to discover new ways to improve and extend people’s lives. Through science-based innovation we address some of society’s most challenging healthcare issues. Working to discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible.
Novartis focuses on innovative patent-protected medicines, generics and eye care products – segments where we have global reach and strong relations with our customers. Research and development (R&D) sits at the core of our business and central to our strategy. Our global organizations for manufacturing, business services and other functions help increase efficiency and promote excellence.
Reimagine what you could do at Novartis.
1642 articles with Novartis
-
A Small Group of Pharma Companies Is Making the Bulk of Medicines Necessary for Developing Countries
11/21/2018
There are 7 billion people in the world. Of those, 5 billion have access to life-saving medications, while 2 billion do not. That is a gap that pharmaceutical companies can help close through increased R&D programs, logistical initiatives and the lowering of prices, the Access to Medicine Foundat... -
According to the American Cancer Society, almost 601,000 people in the U.S. died of cancer in 2017. The two most common types of cancer are lung cancer and breast cancer, followed by colorectal cancer, prostate cancer and stomach cancer.
-
Novartis has been on something of a housecleaning binge since Vasant (Vas) Narasimhan took over the chief executive officer position from Joseph Jimenez in January of this year. On October 30, Novartis indicated it planned to abandon approximately 20 percent of its research projects.
-
Cabaletta Bio launched out of the University of Pennsylvania with an exclusive license deal and two multi-year sponsored research agreements. The fledgling biotech company will work on engineered T cell products for B cell-mediated autoimmune disease.
-
Nektar Therapeutics, based in San Francisco, and New York-based Pfizer are teaming up to evaluate combination regimens in several cancer settings. Those include metastatic castration-resistant prostate cancer (mCRPC) and squamous cell carcinoma of the head and heck (SCCHN).
-
Days after Novartis axed one-fifth of its research programs, the Swiss pharma giant said it intends to seek regulatory approval for 60 new treatments between 2019 and 2021.
-
The U.S. FDA approved Pfizer’s Lorbrena (lorlatinib) for ALK-positive metastatic non-small cell lung cancer (NSCLC) in patients whose disease hasn’t progressed on crizotinib and at least one other ALK inhibitor or for patients whose disease has progressed on alectinib or ceritinib as the first AL...
-
Biopharma companies set to release financial reports next week have reported positive news in recent months.
-
The U.S. Food and Drug Administration (FDA) gave the green light to Hyrimoz, a biosimilar to AbbVie’s blockbuster drug Humira, five years ahead of the time it can be launched in U.S. markets.
-
In an interview with S&P Global Market Intelligence, Alex Hoos, head of oncology at GSK, said the company could narrow its drug development focus to aim at products that will generate growth.
-
To suggest that the pharma industry is a reluctant partner in President Donald Trump’s attempts to decrease drug prices is to overstate the fact. But now the industry appears to be pushing back, at least a little bit.
-
According to Jay Bradner, president of the Novartis Institutes for Biomedical Research, the company is cutting its drug programs from 430 to 340. One of the big areas the company is abandoning is infectious diseases. The decision is a result of a strategic review by Vasant (Vas) Narasimhan, the c...
-
NASH is similar to cirrhosis of the liver but occurs in people that drink little or no alcohol. It is related to the obesity epidemic and affects at least three to five percent of the adult population worldwide. Many believe that combination therapies will be the best way to approach treating NAS...
-
Novartis nAMD Treatment Brolucizumab Shows Superiority Against Regeneron’s Eylea at Two Years
10/29/2018
With fresh two-year data in hand, Novartis remains focused on seeking regulatory approval for brolucizumab, an ophthalmology drug for the treatment of neo-vascular age related macular degeneration.. -
BioSpace Movers and Shakers Oct. 29
10/29/2018
Biopharma companies shore up leadership roles with new hires and appointments, at Axcella Health, Twist Bioscience, and more. -
Compact Imaging Collaborates with Global Pharma to Accelerate Development of Home Monitor for Age-Related Macular Degeneration and Diabetic Retinopathy
10/25/2018
CI’s patented MRO™ (Multiple Reference OCT) technology aims to power affordable personal devices to safely monitor disease progression
-
The European Society of Medical Oncology was in full swing this weekend as multiple companies showed off mid- and late-stage assets that could change the way some patients are treated for their cancer. This morning, BioSpace takes a look at some of the announcements.
-
Gene Therapy, Gene Editing and Immuno-Oncology Creating Thousands of New Job Opportunities
10/22/2018
The U.S. Bureau of Labor Statistics predicts a 7 percent increase in jobs for biomedical engineers and a 13 percent increase in medical scientists. -
BioSpace Movers and Shakers - Oct. 22
10/22/2018
Execs at Novo Nordisk, AbbVie, and more made moves this week. Here's a roundup of those changes. -
Part of the Trump Administration and the U.S. Food and Drug Administration (FDA)’s strategy to push down drug prices is to develop ways to increase competition. As such, the agency launched a Drug Competition Action Plan that has several components.